Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFATC1 | O95644 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 4/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL120724 | 0.82 | HTR7 (0.39) | KMT2ANPC1RAB9AGRM2 | |
| SCHEMBL16465276 | 0.79 | BMPR1A (0.41) | KMT2ANPC1RAB9AGRM2KDM4E | |
| SCHEMBL23632989 | 0.77 | KDM4E (0.40) | KMT2ANPC1KDM4EMEN1POLB | |
| SCHEMBL3860760 | 0.76 | KMT2A (0.40) | KMT2ANPC1RAB9AKDM4EMEN1 | |
| SCHEMBL588860 | 0.74 | KMT2A (0.43) | GSK3BKMT2ANPC1RAB9AKDM4E | |
| SCHEMBL589545 | 0.74 | KMT2A (0.40) | KMT2ANPC1RAB9AKDM4EMEN1 | |
| SCHEMBL6985244 | 0.74 | KMT2A (0.43) | KMT2ANPC1RAB9ADRD3KDM4E | |
| SCHEMBL22655357 | 0.74 | BMPR1A (0.40) | KMT2ANPC1RAB9AKDM4EMEN1 | |
| SCHEMBL15885287 | 0.71 | CNR1 (0.42) | KMT2ANPC1RAB9AKDM4EMEN1 | |
| SCHEMBL17247762 | 0.71 | MAPT (0.46) | KMT2ANPC1RAB9ADRD3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2906539-B1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | HIVIH (FR) | 2017-06-21 | — | — | EP | disclosed |
| US-9475802-B2 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | LABORATOIRE BIODIM (FR) | 2016-10-25 | — | — | US | disclosed |
| US-9475802-B2 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | LABORATOIRE BIODIM (FR) | 2016-10-25 | — | — | US | disclosed |
| US-9475802-B2 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | LABORATOIRE BIODIM (FR) | 2016-10-25 | — | — | US | disclosed |
| US-20150274718-A1 | Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses | LABORATOIRE BIODIM (FR) | 2015-10-01 | — | — | US | disclosed |
| US-20150274718-A1 | Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses | LABORATOIRE BIODIM (FR) | 2015-10-01 | — | — | US | disclosed |
| US-20150274718-A1 | Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses | LABORATOIRE BIODIM (FR) | 2015-10-01 | — | — | US | disclosed |
| EP-2906539-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2015-08-19 | — | — | EP | disclosed |
| WO-2014057103-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2014-04-17 | — | — | WO | disclosed |
| WO-2014057103-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2014-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274718-A1 | Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses | RPL35, EIF2AK2, MAVS | NFATC1 186/4885GSK3B 1951/4885DYRK1A 4442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.